JFL Life SciencesNSE:JFLLIFE 65 ROE % is 11.09% as of Mar. 2025, which is 14% above its 10-year median of 9.73. GuruFocus rates NSE:JFLLIFE with a GF Score™ of 65/100 and a GF Value™ of ₹35.55 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 933 Drug Manufacturers companies, JFL Life Sciences ranks better than 67.85% on this metric.
The historical rank and industry rank for JFL Life Sciences's ROE % or its related term are showing as below:
NSE:JFLLIFE'
s ROE % Range Over the Past 10 Years
Min: 6.03 Med: 9.73 Max: 30.94
Current: 11.09
During the past 7 years, JFL Life Sciences's highest ROE % was 30.94%. The lowest was 6.03%. And the median was 9.73%.
NSE:JFLLIFE's ROE % is ranked better than 67.85% of 933
companies
in the Drug Manufacturers industry
Industry Median: 5.89
vs NSE:JFLLIFE: 11.09
JFL Life Sciences (NSE:JFLLIFE) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is one times the annual (Mar. 2025) net income data. The Revenue data used here is one times the annual (Mar. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
JFL Life Sciences ROE % Related Terms
JFL Life Sciences ROE % Historical Data
* Premium members only.
The historical data trend for JFL Life Sciences's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, JFL Life Sciences's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JFL Life Sciences ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JFL Life Sciences's ROE % distribution charts can be found below:
* The bar in red indicates where JFL Life Sciences's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Mar. 2025) net income data.
ROE % is displayed in the 30-year financial page.
JFL Life Sciences (NSE:JFLLIFE) has a ROE % of 11.09% as of Mar. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on JFL Life Sciences and its competitors. This is 14% above median its historical median of 9.73. Over the past decade, JFL Life Sciences' ROE % has ranged from 6.03 to 30.94. According to the industry distribution chart, JFL Life Sciences ranks #300 out of 933 companies in the Drug Manufacturers industry, placing it in the top 32.2%.
Is JFL Life Sciences' ROE % too high?
JFL Life Sciences' current ROE % of 11.09% is 14% above median its 10-year median of 9.73. Over the past 10 years, this metric has ranged from a low of 6.03 to a high of 30.94. The Drug Manufacturers industry median ROE % is 5.89. JFL Life Sciences' value of 11.09% is 88.3% above this industry median. Based on the distribution chart, JFL Life Sciences ranks #300 out of 933 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, JFL Life Sciences has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JFL Life Sciences' ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, JFL Life Sciences ranks #300 out of 933 companies for ROE %. This puts JFL Life Sciences in the upper half of its industry. The industry median ROE % is 5.89. JFL Life Sciences' value of 11.09% is 88.3% above this benchmark. Historically, JFL Life Sciences' own ROE % has ranged from 6.03 to 30.94 over the past decade. While the company's 10-year median is 9.73 vs. the industry median of 5.89, JFL Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.89, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JFL Life Sciences's current ROE % of 11.09% is 88.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on JFL Life Sciences and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JFL Life Sciences's current ROE % is 11.09%, which is 14% above median its own 10-year median of 9.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JFL Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, JFL Life Sciences (NSE:JFLLIFE) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹35.55, compared to a current price of ₹9.05 — trading 74.5% below its estimated fair value. The current ROE % is 11.09%, which is 14% above median its 10-year median of 9.73 and 88.3% above the Drug Manufacturers industry median of 5.89. JFL Life Sciences' overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For JFL Life Sciences (NSE:JFLLIFE), the current ROE % is 11.09% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JFL Life Sciences (NSE:JFLLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, JFL Life Sciences stock appears to be undervalued.
The current stock price of ₹9.05 is trading 74.5% below its estimated GF Value™ of ₹35.55.
GuruFocus considers JFL Life Sciences to be Significantly Undervalued.
Key valuation signals for NSE:JFLLIFE:
ROE %: 11.09% (14% above median its 10-year median of 9.73)
GF Value™: ₹35.55 vs. price of ₹9.05 (74.5% below fair value)
Industry Position: 88.3% above the Drug Manufacturers median (#300 of 933)
No single metric tells the full story. See the NSE:JFLLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JFL Life Sciences Ltd is engaged in the business of manufacturing pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets and Capsules (B-Lactam) solid oral dosage forms, and general tablets and capsules. Its operating segment comprises of manufacturing and selling of pharmaceutical products. Geographically, the company sells its products both in India and outside India.
65GF Score
Get the complete analysis for NSE:JFLLIFE
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JFLLIFE has been successfully added to your 